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Objective. To assess whether high-molecular-weight proteins excretion predicts outcome and therapy-responsiveness in patients
with FSGS and nephrotic syndrome. Research Design andMethods. Thirty-eight patients measured at biopsy fractional excretion of
IgG (FEIgG) and urinary 𝛼2-macroglobulin/creatinine ratio (𝛼2m/C). Low and high risk groups were defined by cutoffs assessed by
ROC analysis. In all patients first-line therapy was with steroids alone or in combination with cyclophosphamide. Results. 𝛼2m/C
and FEIgG were correlated with segmental sclerosis (𝑟 = 0.546; 𝑟 = 0.522). Twenty-three patients (61%) entered Remission and 9
(24%) progressed to ESRD. Comparing low and high risk groups, by univariate analysis remission was predicted by FEIgG (77%
versus 25%, 𝑃 = 0.016) and 𝛼2m/C (81% versus 17%, 𝑃 = 0.007) and ESRD at best by FEIgG (0% versus 75%, 𝑃 < 0.0001) and
𝛼2m/C (4% versus 67%, 𝑃 < 0.0001). By multivariate analysis FEIgG was the only independent predictor of remission and 𝛼2m/C
the most powerful predictor of ESRD. Low and high risk groups of FEIgG and 𝛼2m/C in combination had very high predictive
value of sustained remission and ESRD in response to therapy. Conclusions. FEIgG and 𝛼2m/C are powerful predictors of outcome
and responsiveness to steroids and cyclophosphamide; their predictive value, if validated in prospective studies, may be useful in
clinical practice suggesting first-line alternative treatments in high risk patients.
1. Introduction
Idiopathic focal segmental glomerulosclerosis (FSGS) is a
clinicopathologic entity characterized by alteration of the
molecular architecture of podocytes and slit diaphragmswith
disruption of the glomerular filtration barrier (GFB) and con-
sequent proteinuria. Studies of animal models and familiar
forms elucidated several molecular defects responsible for
podocyte damage [1–3]. An increased understanding of the
molecular mechanisms involved in podocyte damage has not
been associated as yet with improved outcome prediction
[2]; thus at present the best favourable prognostic factor for
FSGS with nephrotic syndrome (NS) is still remission in
response to corticosteroids [4–6]. The etiology of idiopathic
FSGS is unknown. An immunological pathogenesis has been
hypothesized, at least in some patients, with a clone of T
lymphocytes secreting a permeability factor that alters GFB
[7]. Recently some doubts have been raised regarding the
autoimmune pathogenesis of FSGS (review in [8]), supported
in part by the observation that certain “immunosuppressive”
agents (dexamethasone and cyclosporine A) reduce protein-
uria by a direct stabilization of the podocyte cytoskeleton [9–
12]. On the basis of the immunologic hypothesis, idiopathic
FSGS has been treated over time with older and more recent
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immunosuppressive agents, but treatment is still largely
empirical due to different and unpredictable responses and
the lack of reliable predictors for drug responsiveness. As
early as 1976, Hardwicke et al [13]. showed that FSGS is
characterized by elevated excretion of the high-molecular-
weight (HMW) protein IgG. In a pilot observational study
[14], we showed that baseline fractional excretion of IgG (FE
IgG) is a reliable predictor of ESRD and remission and that
responsiveness to steroids alone or steroids plus cyclophos-
phamide is dependent on the value of FE IgG.The aim of the
study was to evaluate in a long-term observational study the
predictive value of functional outcome and responsiveness
to steroids alone or in combination with cyclophosphamide
of baseline excretion of HMW proteins (IgG, 150 kDa; 𝛼2-
macroglobulin, 720 kDa) asmarkers of selectivity ofGFB [15].
2. Subjects and Methods
2.1. Patients. The present study is a follow-up of our previous
study [14]; the number of patients has increased from 29 to 38
with inclusion of 9 patients diagnosed after the publication of
the previous study; all patients arewhite Europeans. Inclusion
criteria are presence of NS defined as 24 hour proteinuria
≥3.5 g; at least 6 glomeruli in biopsy specimens; mea-
surement at biopsy of urinary 𝛼2-macroglobulin/creatinine
ratio (𝛼2m/C), FE IgG, and fractional excretion of 𝛼1-
microglobulin (FE 𝛼1m), 24 hour proteinuria and urinary
protein/creatinine ratio; baseline sCr <2.0mg/dL and eGFR
≥30mL/min/1.73m2; follow-up of at least 24 months in
patients not progressing to ESRD; overall follow-up: 96 ± 67
months (12–234); and follow-up of patients not progressing to
ESRD: 115 ± 63months (24–234). The study is in adherence
to the Declaration of Helsinki. All patients gave informed
consent to data handling. The clinical features of patients are
reported in Table 1.
2.2. Renal Biopsies. Renal biopsies were performed by stan-
dard histologic and immunofluorescence methods [16]; 35
biopsies were available for analysis and were evaluated by
the pathologist P. N.: the types of histologic variants were
defined according to the Columbia classification [17]: NOS
71% (𝑛 = 25), cellular 23% (𝑛 = 8), tip 3% (𝑛 = 1), and
perihilar 3% (𝑛 = 1). The mean number (±SD) of glomeruli
in biopsies was 14 ± 6 (6–32). The percentages of glomeruli
with global glomerulosclerosis (GGS) and focal segmental
glomerulosclerosis (SS) were 7 ± 10% (0–37%) and 21 ± 15%
(5–70%), respectively.The extent of tubulointerstitial damage
(TID) was evaluated semiquantitatively: tubular atrophy,
interstitial fibrosis, and inflammatory cell infiltration were
graded 0, 1, or 2 if absent, focal, or diffuse (TID global score:
0–6); mean (±SD) of TID score: 2.0 ± 1.5 (0–6).
2.3. Laboratory Analysis. For each patient a 24 hour urine
collection and a secondmorning urine sample were obtained
at biopsy. Urinary proteins were measured by the Coomassie
blue method and expressed in grams/24 hours (24 hP) and
as protein/creatinine ratio (UP/C: mg/1g of urinary creati-
nine). Serum and urinary creatinine were measured with
Table 1: Baseline clinical characteristics of 38 patients with FSGS
and NS.
No. of patients 38 Range
Age (yrs) 39 ± 18 14–80
Sex (M/F) 21/17
eGFR (mL/min/1.73m2) 80 ± 31 30–123
eGFR <60mL/min/1.73m2 29%
BP ≥140/90mmHg 55%
Serum albumin 2.26 ± 0.72 0.98–3.76
24 hP 8.5 ± 5.7 3.5–32.7
UP/C 6111 ± 4246 253–20283
𝛼2m/C 3.4 ± 5.2 0–18.7
FE IgG 0.091 ± 0.112 0.003–0.534
FE 𝛼1m 0.305 ± 0.260 0.007–0.945
No. of glomeruli in RB (no. 35) 14 ± 6 6–32
GGS% 7 ± 10 0–37
TID score 2.0 ± 1.5 0–6
SS% 21 ± 15 5–70
Overall follow-up (mths) 96 ± 67 12–236
Follow-up of pts. without ESRD 115 ± 63 24–236
eGFR: estimated GFR; BP: blood pressure; 24 hP: 24 hour proteinuria;
UP/C: urinary protein/creatinine ratio; 𝛼2m/C: urinary 𝛼2m/creatinine
ratio; FE IgG: fractional excretion of IgG; FE 𝛼1m: fractional excretion of
𝛼1-microglobulin; RB: renal biopsy; GGS: global glomerular sclerosis; TID
score: tubulointerstitial damage score; SS: segmental sclerosis.
standard automated techniques. Baseline and last eGFR were
calculated according to the 4-variable MDRD formula [18].
IgG, 𝛼1-microglobulin (𝛼1m), and 𝛼2-macroglobulin (not
evaluated in the previous study) [14] were measured by
immunonephelometry as described [14]. FE IgG and FE
𝛼1m were calculated according to the formula (urinary pro-
tein/serum protein × sCr/uCr) × 100; 𝛼2m/C was expressed
in mg/1 g urinary creatinine.
2.4. End Points. Two end points were considered: (1) ESRD
with start of renal replacement therapy and (2) remission:
complete (24 hP < 0.2 g/day) or partial (24 hP < 2.0 g/day)
with stable renal function.
2.5. Predictors of FunctionalOutcome. Nine factorswere eval-
uated for their predictive value of outcome: eGFR,𝛼2m/C, FE
IgG, FE a1m, 24 hP, UP/C, GGS, TID score and SS. For each
parameter the cutoff point with the highest sensitivity and
specificity for progression to ESRD assessed by ROC analysis
was used to define low and high risk groups.
2.6. Treatment. All 38 patients started treatmentwith steroids
soon after biopsy: 26 of them (68%) with 3 i.v. methylpred-
nisolone pulses (1 g/day on alternate days) followed by oral
prednisone (1mg/kg/day with tapering) and 12 patients (32%)
started treatment with oral prednisone (1mg/kg/day with
tapering). The duration of oral treatment with prednisone
in all 38 patients was 9.3 ± 5.5 months [4–32]. Steroid
responsiveness (complete or partial remission) was assessed
at the end of the fourthmonth of steroid treatment; 13 patients
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Table 2: Area under the ROCcurve (AUC), cutoffs, sensitivity, and specificity for progression to ESRDof clinical, proteinuric, and histological
parameters.
Risk factors AUC 𝑃 Cutoff Sensitivity % Specificity %
eGFR 0.489 (0.784) ≥68 67 52
FE IgG 0.973 (<0.0001) ≥0.112 100 90
UP/C 0.904 (<0.0001) ≥5980 100 76
FE 𝛼1m 0.897 (<0.0001) ≥0.362 78 93
𝛼2m/C 0.891 (<0.0001) ≥4.79 89 86
24 hP 0.872 (0.001) ≥6.8 100 69
GGS 0.470 (0.798) ≥7.5% 38% 59%
TID score 0.477 (0.844) ≥3.5 25% 93%
SS 0.701 (0.087) >16% 88% 59%
eGFR: estimated GFR; FE IgG: fractional excretion of IgG; UP/C: urinary protein/creatinine ratio; FE 𝛼1m: fractional excretion of 𝛼1-microglobulin; 𝛼2m/C:
urinary 𝛼2-macroglobulin/creatinine ratio; 24 hP: 24 hour proteinuria; GGS: global glomerular sclerosis; TID score: tubulointerstitial damage score; SS:
segmental sclerosis.
(34%) were steroid responsive; 25 patients (66%) were unre-
sponsive; in 28 patients (20 steroid unresponsive and 8 steroid
responsive but relapsing) treatment with cyclophosphamide
(CYP) was associated with steroids: in 10 patients with i.v.
monthly pulses of 0.5–0.75 g for 3–6months and in 18 patients
with oral CYP (1.5–2.0mg/kg/day for 3.7 ± 1.6 months (2–
6.5); lower doses for elderly patients and patients with renal
function impairment.
2.7. Statistical Methods. The SPSS18 software program was
used for statistical analysis. Differences between groups were
determined using the unpaired 𝑡-test and theMann-Whitney
𝑈 test. Correlations were assessed with the Spearman test.
The receiver operating characteristics (ROC) curve was used
to determine cutoff values for progression to ESRD of
functional, proteinuric, and histologic parameters. For the
end point ESRD and remission survival curves according
to Kaplan-Meier were used to evaluate differences between
low and high risk groups; equality of survival curves was
tested by log-rank test. Multivariate Cox regression analysis
identified the independent predictors of ESRDand remission.
The significance level was defined as 𝑃 < 0.05.
3. Results
3.1. Correlation between Histologic Lesions and Proteinuric
Markers. The percentage of SS was highly correlated with
𝛼2m/C (𝑟 = 0.546, 𝑃 = 0.001), FE IgG (𝑟 = 0.522, 𝑃 = 0.001)
and FE 𝛼1m (𝑟 = 0.373, 𝑃 = 0.027), but not with 24 hP and
UP/C.The patients with SS below versus above the SSmedian
value (16%) had significantly different levels of 𝛼2m/C (0.5 ±
1.4 versus 5.7 ± 6.1, 𝑃 < 0.0001), FE IgG (0.038 ± 0.043
versus 0.116 ± 0.102, 𝑃 = 0.001), and FE 𝛼1m (0.177 ± 0.117
versus 0.320 ± 0.178, 𝑃 = 0.009), while the difference was not
significant for 24 hP and UP/C. Other chronic lesions (GGS
and TID scores) did not show a significant correlation with
all proteinuric markers.
3.2. Correlation between Baseline Functional and Proteinuric
Parameters and Last eGFR. The eGFR at last observation was
highly correlated with baseline eGFR (𝑟 = 0.502, 𝑃 = 0.001),
𝛼2m/C (𝑟 = −0.546, 𝑃 < 0.0001), FE IgG (𝑟 = −0.565, 𝑃 <
0.0001), and FE 𝛼1m (𝑟 = −0.563, 𝑃 < 0.0001); lower degree
of correlation was found for 24 hP (𝑟 = −0.357, 𝑃 = 0.028)
and UP/C (𝑟 = −0.394, 𝑃 = 0.014).
3.3. ROC Analysis for Progression to ESRD, Sensitivity and
Specificity of Cutoffs. To evaluate the predictive value of
functional outcome low and high risk groupswere defined for
all parameters according to cutoffswith the highest sensitivity
and specificity for progression to ESRD assessed by ROC
analysis (Table 2 and Figure 1). FE IgG showed the largest area
under the ROC curve: 0.973; cutoff ≥0.112; sensitivity: 100%;
specificity: 90%.
3.4. Overall Functional Outcome. Nine patients (24%) re-
ached ESRD and started renal replacement therapy after 34 ±
35months (12–119); 23 patients (61%) entered remission after
15 ± 19months (range 1–75); 6 patients (16%) had persistent
NS with stable eGFR after 60 ± 29 months (24–73): baseline
versus last eGFR: 63 ± 25 versus 60 ± 36mL/min/1.73m2,
𝑃 = ns.
The ESRD patients compared to remission patients had
significantly higher values of 24 hP, UP/C, 𝛼2m/C, FE IgG,
FE 𝛼1m and SS (Table 3), no significant differences for
age, baseline eGFR, percentage of eGFR <60mL/min, high
baseline blood pressure, GGS and TID scores.
3.5. Prediction of Remission as First Event after NS. By uni-
variate analysis only FE IgG (77% versus 25%, 𝑃 = 0.016)
and 𝛼2m/C (81% versus 17%, 𝑃 = 0.007) were predictors of
remission in patients with a value below or above their cutoff
(Table 4). By multivariate analysis according to Cox model
including FE IgG and 𝛼2m/C, the independent predictor of
remission was FE IgG (HR: 0.18, CI 0.041–0.753, 𝑃 = 0.019).
Prediction of remission increased to 83% versus 11% (𝑃 =
0.008) in patients with both FE IgG and 𝛼2m/C below or
above their respective cutoffs (Table 4 and Figure 2).
3.6. Relationship between Remission and Type of Treatment.
All 23 patients who entered remission started therapy soon
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Figure 1: Area under the ROC curves (AUC) for progression to ESRD of the parameters eGFR, 24 hour proteinuria (24 hP), fractional
excretion of IgG (FE IgG), and urinary 𝛼2-macroglobulin/creatinine ratio (𝛼2m/C).
Table 3: Clinical, proteinuric, and histological parameters in patients who progressed to ESRD compared to patients who entered remission
as first event.
ESRD Remission 𝑃
No. of patients 9 23
Age (yrs) 33 ± 21 41 ± 17 ns
Sex (M/F) 6/3 14/9 ns
Baseline eGFRmL/min/1.73m2 76 ± 30 85 ± 31 0.46
eGFR <60mL/min/1.73m2 22% 26% ns
BP ≥140/90mmHg 56% 57% ns
24 hP 14.1 ± 8.6 7.2 ± 3.0 0.003
UP/C 10486 ± 4100 5125 ± 3581 0.001
𝛼2m/C 9.5 ± 6.4 1.2 ± 2.1 <0.001
FE IgG 0.234 ± 0.144 0.051 ± 0.050 <0.001
FE 𝛼1m 0.485 ± 0.204 0.210 ± 0.139 <0.001
Segmental sclerosis % 26 ± 13 18 ± 15 0.043
Global glom. sclerosis % 7 ± 13 5 ± 7 0.91
TID score 2.0 ± 2.1 1.6 ± 1.3 0.85
Time to ESRD (mths) 34 ± 35
Time to first remission (mths) 15 ± 19
eGFR: estimated GFR; BP: blood pressure; 24 hP: 24 hour proteinuria; UP/C: urinary protein/creatinine ratio; 𝛼2m/C: urinary 𝛼2-macroglobulin/creatinine
ratio; FE IgG: fractional excretion of IgG; FE 𝛼1m: fractional excretion of 𝛼1-microglobulin; GGS: global glomerular sclerosis; TID score: tubulointerstitial
damage score; SS: segmental sclerosis.
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Table 4: ESRD and remission rate in 38 patients with FSGS and NS according to functional, proteinuric, and histological markers.
ESRD no. 9 (24%) Remission no. 23 (61%)
FE IgG 0 versus 1 (26 versus 12) 0% versus 75% (<0.0001) 77% versus 25% (0.016)
24 hP 0 versus 1 (20 versus 18) 0% versus 50% (0.001) 75% versus 44% (0.10)
UP/C 0 versus 1 (22 versus 16) 0% versus 56% (<0.0001) 73% versus 44% (0.11)
eGFR 0 versus 1 (20 versus 18) 30% versus 17% (0.23) 65% versus 56% (0.10)
FE 𝛼1m 0 versus 1 (28 versus 10) 7% versus 70% (<0.0001) 71% versus 30% (0.06)
𝛼2m/C 0 versus 1 (26 versus 12) 4% versus 67% (<0.0001) 81% versus 17% (0.007)
FE IgG 0 + 𝛼2m/C 0 (23) versus FE IgG 1 + 𝛼2m/C 1 (9) 0% versus 89% (<0.0001) 83% versus 11% (0.008)
SS 0 versus 1 (17 versus 18) 6% versus 39% (0.018) 82% versus 44% (0.11)
GGS 0 versus 1 (21 versus 14) 24% versus 21% (0.80) 67% versus 57% (0.71)
TID score 0 versus 1 (22 versus 13) 27% versus 15% (0.39) 64% versus 62% (0.26)
FE IgG 0 versus 1: < versus ≥ 0.112; 24 hP 0 versus 1: < versus ≥ 6.8 g/24 hours; UP/C 0 versus 1: < versus ≥ 5980mg/g uCr; eGFR 0 versus 1: < versus ≥
68mL/min/1.73m2; FE 𝛼1m 0 versus 1: < versus ≥ 0.362; 𝛼2m/C 0 versus 1: < versus ≥ 4.79mg/g uCr; SS 0 versus 1: < versus ≥ 16%; GGS 0 versus 1: < versus
≥ 7%; TID score 0 versus 1: < versus ≥ 3.
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Figure 2: Probability of ESRD and remission in patients with FE IgG and 𝛼2m/C below (0) or above (1) their respective cutoffs.
after renal biopsy with steroids; 13 patients (34%) were steroid
responsive and entered remission within 4 months, and 10
patients were steroid unresponsive with persistent NS at the
end of fourth month, when CYP treatment was associated:
8 of them (21%) entered remission; the overall remission
rate in response to steroids or steroids + cyclophosphamide
was 55%. Two patients were unresponsive to steroids and
CYP in combination: one entered remission after treatment
with mycophenolate mofetil (2 g/day for 18 months) and the
other after treatment with 400mg × 2/day for 43 months
of pentoxifylline, a non-specific phosphodiesterase inhibitor
with anti-inflammatory properties [19, 20] which reduces
proteinuria in membranous [21] and diabetic nephropathy
[22] and slows the GFR decline in CKD [19]. Ten of the
13 steroid-responsive patients had 13 relapses; 2 of them
entered sustained remission after a second treatment with
steroids alone and 5 patients after one or more treatments
with steroids plus CYP; 3 patients became steroid dependent;
of these one patient entered remission after cyclosporine
A (200mg/day with tapering for 32 months); one patients
was unresponsive to treatment with rituximab (600mg × 2,
18 months apart) and one unresponsive to treatment with
mycophenolate mofetil (2 g/day for 12 months).
3.7. Sustained Remission. At last observation after 138 ± 56
months, 21 out of 23 patients with remission as first event
after NS had sustained remission for 104 ± 54 months with
steroids alone (𝑛 = 5), steroids + CYP (𝑛 = 13), or other
treatments in 3 patients unresponsive to steroids and CYP
(𝑛 = 2) or steroid dependent (𝑛 = 1): mycophenolate
mofetil (no. 1), pentoxifylline (𝑛 = 1), and cyclosporine
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A (𝑛 = 1), respectively; 18 (86%) out of 21 patients who
attained sustained remission had FE IgG and 𝛼2m/C below
the cutoff. Remission was complete in 13 patients and partial
in 8 patients; baseline versus last values of eGFR and 24 hP
were 83 ± 31 versus 80 ± 23mL/min/1.73m2 (𝑃 = ns) and
7.3±3.1 versus 0.28±0.39 g/24 hours,𝑃 < 0.0001, respectively.
3.8. ESRD Prediction. By univariate analysis, the most pow-
erful predictors of ESRD were FE IgG (0% versus 75% 𝑃 <
0.0001), 𝛼2m/C (4% versus 67%, 𝑃 < 0.0001), and FE 𝛼1m
(7% versus 70%, 𝑃 < 0.0001) in patients with baseline value
below or above their cutoff. All other functional, proteinuric,
and histologic markers had lower predictive value (Table 4).
By multivariate analysis according to Cox model including
UP/C, FE IgG, 𝛼2m/C, and FE 𝛼1m, the most powerful
independent predictors of ESRDwere𝛼2m/C (HR: 16, CI 1.8–
142, 𝑃 = 0.013) and FE𝛼1m (HR: 5.9, CI 1.1–31.3, 𝑃 = 0.038).
ESRD prediction increased to 0% versus 89% (𝑃 < 0.0001) in
patients with both FE IgG and 𝛼2m/C below or above their
respective cutoffs (Table 4 and Figure 2).
3.9. Relationship between ESRD, Proteinuric Markers, and
Type of Treatment. The 9 ESRD patients started steroid
therapy soon after biopsy: 8 with 3 i.v. methylprednisolone
pulses (1 g/day on alternate days) followed by oral prednisone
1mg/kg/day with tapering for 9±3months (5–12); all patients
were steroid unresponsive at the end of the fourth month; in
8 patients cyclophosphamide treatment was associated: in 4
patients with 0.5–0.75 g iv pulsesmonthly for 3–6months and
in 4 patients with 1.5–2.0mg/day for 2.5 ± 1.0months (2–4).
All 9 ESRDpatients were steroid unresponsive and 8 steroid +
CYPunresponsive; in all patients FE IgGwas above the cutoff.
3.10. Relationship between FE IgG and Responsiveness to
SteroidsAlone or Steroids Plus Cyclophosphamide. FE IgGwas
significantly lower in patients responsive to steroids alone
versus patients responsive only to steroids plus CYP (0.034 ±
0.047 versus 0.084 ± 0.038, 𝑃 = 0.008) and versus patients
unresponsive to steroids plus CYP and progressing to ESRD
(0.034 ± 0.047 versus 0.234 ± 0.144, 𝑃 < 0.0001); FE IgG was
also lower in patients responsive only to steroids plus CYP
versus patients unresponsive to steroids plus CYP (0.084 ±
0.038 versus 0.234 ± 0.144, 𝑃 = 0.008).
4. Discussion
Our data show that the excretion ofHMWproteins (𝛼2m and
IgG) is highly correlated with SS (𝑟 = 0.546 and 0.522, resp.);
this observation suggests that development and percentage
of SS are associated with loss of selectivity of GFB of which
FE IgG and 𝛼2m/C are reliable markers [15]. By contrast
all proteinuric markers did not correlate with the chronic
lesions GGS and TID scores. This lack of correlation may
be dependent on time of biopsy in relation to the onset of
NS; 55% of our patients had biopsies within 4 months after
the onset of NS (37% within 2 months), a time that may be
too short for the development of chronic lesions, while SS
develops early in the disease course as is present in 15 ± 11%
versus 29±17% of glomeruli (𝑃 = 0.017) in patients biopsied
within 4 months or later.
FE IgG and 𝛼2m/C show the highest prediction of
functional outcome; by univariate analysis their prediction
of ESRD and remission is higher than that of all other
markers, including 24 hP, the most widely used marker of
NS severity. By multivariate analysis FE IgG is the only
independent predictor of remission and 𝛼2m/C the most
powerful independent predictor of ESRD.These data suggest
that themore severe theGFB alteration and themore elevated
the excretion of HMW proteins, the higher the risk of
progressive renal damage, mediated at least in part by TID,
as suggested by the high correlation between FE IgG and FE
𝛼1m (𝑟 = 0.759, 𝑃 < 0.0001) and between FE 𝛼1m and last
eGFR (𝑟 = −0.563). Conversely the lower the excretion of FE
IgG and 𝛼2m/C, the higher the probability of remission.
A high predictive value of outcome of HMW pro-
tein excretion has been observed in other types of GN;
IgG in glomerulonephritis [23, 24], idiopathic membranous
nephropathy [25–27], crescentic [28] and noncrescentic IgA
nephropathy [29, 30] with different cutoffs for each type
of GN; IgM (MW: 900 kDa) in ANCA-associated renal
vasculitis [31] and type 2 diabetic nephropathy [32].
FE IgG is also a predictor of responsiveness to steroids
alone or in combination with CYP; it is significantly lower in
patients responsive to steroids alone versus patients respon-
sive only to steroids andCYP in combination (𝑃 = 0.008) and
versus patients unresponsive to both drugs and progressing to
ESRD (𝑃 < 0.0001).
Progression to ESRD in patients treated with steroids +
CYP according to FE IgG and 𝛼2m/C below or above their
cutoff is 0% versus 89% (𝑃 < 0.0001), suggesting that this
type of therapy prevents progression in all patients with low
risk profile. Sustained remission, assessed according to FE
IgG and 𝛼2m/C in combination, is 83% versus 11% (𝑃 =
0.008), suggesting that low risk profile is associated with a
very high percentage of sustained remission. The present
study in comparison with our previous study [14] includes
some interesting new data: (1) the excretion of HMWprotein
𝛼2-macroglobulin, strongly correlated with the percentage of
SS, in combination with FE IgG, increases the prediction of
remission in low risk patients (83%) and progression to ESRD
in high risk patients (89%). (2) The long-term follow-up of
patients not progressing to ESRD shows that baseline low FE
IgG and 𝛼2m/C below their cutoff are long-term predictors
of sustained remission: 21 out of 23 patients who attained
remission as first event after NS had sustained remission
(follow-up 138 ± 56 months); 18 of these patients had FE
IgG and 𝛼2m/C below the cutoff: 15 treated with steroids
alone (𝑛 = 4) or in combination with CYP (𝑛 = 11) and
3, unresponsive to steroids plus CYP (𝑛 = 2) or steroid
dependent (𝑛 = 1), after treatment with mycophenolate
mofetil (𝑛 = 1), pentoxifylline (𝑛 = 1), and cyclosporine A
(𝑛 = 1). Thus a mild baseline alteration of GFB suggested by
low FE IgG and 𝛼2m/C is a long-term predictor of sustained
remission and shows that responsiveness to steroids plus CYP
is less disappointing than usually stated [33] if evaluated in
low risk patients since 11 out of 18 low risk patients (61%)
are responsive to steroids plus CYP. (3) The prediction of
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progression to ESRD by high FE IgG and 𝛼2m with baseline
value below or above their cutoff (0% versus 89%) suggests
that this type of therapy prevents progression only in low risk
patients.
Thus the availability of baseline biomarkers able to
evaluate risk profiles and responsiveness to steroids alone
or in combination with cyclophosphamide may improve
clinical practice; if the predictive value of outcome and
responsiveness to steroids alone or in combination with CYP
of these biomarkers can be validated in prospective studies,
the usual approach to treatment may change suggesting a
first-line therapy with alternative agents in high risk patients
soon after biopsy and not later in the course of disease
when some degree of progressive chronic damage may have
occurred. Early start of therapy after disease onset is very
important; in our patients with FE IgG and 𝛼2m/C below
the cutoff remission rate was 93% versus 60% (𝑃 = 0.047)
in patients biopsied within four months after the onset of NS
or later.
For the treatment of patients unresponsive to steroids
alone or associated with alkylating agents, several other
more or less recent agents, have been used (review in
[2]): calcineurin inhibitors (cyclosporine A, tacrolimus),
mycophenolate mofetil, monoclonal antibodies (rituximab,
adalimumab), rosiglitazone, and galactose with variable and
unpredictable results due to a lack of reliable outcome
predictors. It is reasonable to assume that FE IgG and 𝛼2m/C
might have a predictive value for responsiveness also to
these agents; a recent study [34] of idiopathic membranous
nephropathy showed that FE IgG predicts remission at 12
months in patients treated with rituximab.
The main limitation of this study is its long-term uncon-
trolled observational design in a rather small group of
patients with idiopathic FSGS. It should be taken into
account that FSGS is a rather uncommon disease and the
suggestion that both well-conducted observational studies
and randomized controlled trials play a complementary and
valuable role in renal diseases [35].
In conclusion this study identifies baseline biomarkers
able to evaluate the degree of GFB alteration and predict
functional outcome and responsiveness to steroids and CYP.
The ability of these biomarkers to identify at baseline patients
unresponsive to steroids and CYP, if validated in prospective
studies, may improve clinical practice, suggesting the choice
of first-line alternative treatments which may be more suc-
cessful if started early in the disease course. A validation of the
predictive value of outcome and responsiveness to new drugs
of these biomarkers in large patient cohorts is warranted.
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